Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Nuvalent, Inc.NASDAQ: NUVL
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$1.39, compared with -$1.18 a year earlier. Trailing-twelve-month EPS (Basic) was -$6.06.
Context
- EPS (Basic) grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 11 analysts of -$5.65 (+3.5%) for the fiscal year ending Dec 2026, a step up from the -48.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.39+12.0% QoQ
- Last fiscal yearDec 2025
- -$5.85-48.9% YoY
- LTMMar 2026
- -$6.06-38.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.8% | -1.6% | +16.2 pp |
| 1 year | -48.9% | +3.5% | +52.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (5.85) USD
- Year-over-year change
- -48.9%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.85) | -48.9% |
| FY2024 | 2024-12-31 | (3.93) | -81.1% |
| FY2023 | 2023-12-31 | (2.17) | -31.5% |
| FY2022 | 2022-12-31 | (1.65) | +22.5% |
| FY2021 | 2021-12-31 | (2.13) | — |
EPS (Basic) vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -38.0% is the 5th highest of 9, against a peer median of -17.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $3.58 USD | +160.1% | — | |
| LTM Sep 2026 | -$2.9 USD | +6.5% | — | |
| LTM Jun 2026 | -$3.75 USD | +26.0% | — | |
| FY2025 | -€4.65 EUR | -66.1% | — | |
| LTM Sep 2026 | -$4.74 USD | +15.2% | — | |
| LTM Sep 2026 | -$5.09 USD | -12629.9% | — | |
| LTM Mar 2026 | -$6.06 USD | -38.0% | — | |
| LTM Jun 2026 | -$7.21 USD | -41.1% | — | |
| LTM Jun 2026 | -$7.64 USD | -81.5% | — | |
| Peer median (excluding NUVL) | — | -17.3% | — | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
| Selling, General & Admin | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M |
| Operating Expenses | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M |
| Depreciation & Amortization | 215K | 0 | 0 | 280.37M | 414.31M |
| EBITDA | (46.12M) | (81.85M) | (126.22M) | 20.38M | (10.49M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.82M) | (86.11M) | (149.49M) | (280.37M) | (414.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 23.27M | 38.32M | 44.74M |
| Interest Expense | 0 | 0 | 23.27M | 0 | 0 |
| Other Income / Expenses | (521K) | 4.25M | 23.27M | 20.38M | (10.49M) |
| Income Before Tax | (46.34M) | (81.85M) | (126.22M) | (259.99M) | (424.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 764K | 585K |
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| EPS (Diluted) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| Weighted Avg Shares | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
| Weighted Avg Shares (Diluted) | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.